Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools
- Resource Type
- Authors
- Richard O'Kennedy; Julia Zapatero-Rodríguez; Shikha Sharma
- Source
- Biotechnology advances. 35(2)
- Subject
- 0301 basic medicine
Male
medicine.medical_specialty
Patient welfare
Biopsy
Point-of-Care Systems
Bioengineering
Clinical settings
Disease
Bioinformatics
Diagnostic tools
Applied Microbiology and Biotechnology
Management of prostate cancer
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Prostate
Biomarkers, Tumor
Medicine
Humans
Intensive care medicine
business.industry
Prostatic Neoplasms
Diagnostic marker
Prostate-Specific Antigen
medicine.disease
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Reagent Kits, Diagnostic
business
Biotechnology
- Language
- ISSN
- 1873-1899
The increased incidence and the significant health burden associated with carcinoma of the prostate have led to substantial changes in its diagnosis over the past century. Despite technological advancements, the management of prostate cancer has become progressively more complex and controversial for both early and late-stage disease. The limitations and potential harms associated with the use of prostate-specific antigen (PSA) as a diagnostic marker have stimulated significant investigation of numerous novel biomarkers that demonstrate varying capacities to detect prostate cancer and can decrease unnecessary biopsies. However, only a few of these markers have been approved for specific clinical settings while the others have not been adequately validated for use. This review systematically and critically assesses ongoing issues and emerging challenges in the current state of prostate cancer diagnostic tools and the need for disruptive next generation tools based on analysis of combinations of these biomarkers to enhance predictive accuracy which will benefit clinical diagnostics and patient welfare.